Mes choix et mouvements sont basés sur l'analyse technique des graphiques,merci pour votre attention et fidélité,le succès de chaque individu dépend de son fond, le dévouement,le désir et la motivation. Soutenir trades actions biotechs en faisant un Don via le bouton Paypal(totalement sécurisé) merci pour vôtre contribution.
Articles les plus consultés
-
francis 13 Version sans publicité Marchés Actualités Analyses Crypto Fonds Graphiques Technique Brokers Outils Portefe...
-
6% Hydroxyethyl Starch 130 / 0.4 in 0.9% Injection de chlorure de sodium (Voluven 500 mL freeflex flexible en plastique intraveineuse solut...
-
Pre Market Top Gainers prénom Dernier Chg. % Vol. Iridium 14.95 + 39.07% 0,60K Mondialisation de l'Inde. 0,4800 + 18,52% 1,80K...
-
Top Gaining Stocks % Chg Dernier Symb Compagnie Le volume 16,22% 2.15 SRNE Sorrento Therapeut 7030 10,92% 2,64 CIE Cobalt Inte...
-
Pre Market Top Gainers prénom Dernier Chg. % Vol. Oracle Corporation 51.30 + 10,73% 58.90K Staples Inc 9.25 + 6,81% 12,31K Delcat...
-
Pre Market Top Gainers prénom Dernier Chg. % Vol. Delcath 0.1230 + 24,24% 196,67K Neos Therapeutics I. 10.50 +16.67% 34.36K Enpha...
-
Citoyens_Français @citoyenneFrance 8 juin Plus Attali : « Les élus n’ont plus de pouvoir et voici votre avenir » - Effr......
-
Pre Market Top Gainers prénom Dernier Chg. % Vol. Lipocine In 5.32 + 32,34% 38.64K Enphase Energy Inc 0,938 + 17,57% 10,37K Delca...
-
28 juin 2017 Nom du médicament et numéro de demande Ingrédient actif Formulaire de posologie / itinéraire Soumission Compagnie ...
-
Plus fortes hausses en préouverture Nom Dernier Var.% Vol. DragonWave Inc 1,3900 +25,23% 3,55K Alibaba 139,95 +11,35% 1,40M MoSys...
mardi 19 juin 2018
ITM: FDA Acceptance of IND to Advance Phase III Clinical Trial COMPETE with Solucin® for Treatment of GEP-NET in the U.S. | Business Wire
ITM: FDA Acceptance of IND to Advance Phase III Clinical Trial COMPETE with Solucin® for Treatment of GEP-NET in the U.S. | Business Wire: ITM announced today that the U.S. FDA has accepted the Investigational New Drug Application to advance its radiopharmaceutical to a phase III trial
la bourse et toutes ses actions tous pays
Insulet to Unveil New Omnipod® DASHTM System and Present Innovative Research at the American Diabetes Association's 78th Scientific Sessions | Business Wire
Insulet to Unveil New Omnipod® DASHTM System and Present Innovative Research at the American Diabetes Association's 78th Scientific Sessions | Business Wire: Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management Syste
la bourse et toutes ses actions tous pays
lundi 18 juin 2018
ObsEva's EDELWEISS Trial Hits All Goals In Endometriosis-associated Pain
la bourse et toutes ses actions tous pays
ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer | Business Wire
ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer | Business Wire: ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that t
la bourse et toutes ses actions tous pays
BioTrace Medical Announces Key Events Featuring Tempo® Lead at TVT 2018 | Business Wire
BioTrace Medical Announces Key Events Featuring Tempo® Lead at TVT 2018 | Business Wire: BioTrace Medical, Inc., the leader in innovative temporary pacing technology, today announced the company’s key activities at the Transcatheter Valve
la bourse et toutes ses actions tous pays
dimanche 17 juin 2018
Bonne fête des papas
la bourse et toutes ses actions tous pays
vendredi 15 juin 2018
Cerus Presents Results of European Phase 3 Chronic Anemia Study at the 23rd Congress of European Hematology Association | Business Wire
Cerus Presents Results of European Phase 3 Chronic Anemia Study at the 23rd Congress of European Hematology Association | Business Wire: Cerus Corporation (Nasdaq: CERS) announced that results from SPARC, the Company’s European Phase 3 study evaluating the efficacy and safety of INTERCE
la bourse et toutes ses actions tous pays
Inscription à :
Articles (Atom)